Cross-priming of long lived protective CD8+ T cells against Trypanosoma cruzi infection: Importance of a TLR9 agonist and CD4+ T cells

Vaccine

Volumn 25, Issue 32, 2007, Pages 6018-6027

  de Alencar, Bruna C G ^a   Araújo, Adriano F S ^a   Penido, Marcus L O ^b   Gazzinelli, Ricardo T ^b   Rodrigues, Mauricio M ^a  

^a FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^b FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

Author keywords

Amastigotes; CpG ODN; Trypanosoma cruzi; Vaccination

Indexed keywords

ALUMINUM POTASSIUM SULFATE; CPG OLIGODEOXYNUCLEOTIDE; GLUTATHIONE TRANSFERASE; GLUTATHIONE TRANSFERASE P4 P7; RECOMBINANT PROTEIN; THREONYLGLUTAMYLTRYPTOPHYLTHREONYLGLYCYLGLUTAMINYLISOLEUCINE; TOLL LIKE RECEPTOR 9; UNCLASSIFIED DRUG;

AGONIST; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CONTROLLED STUDY; CROSS PRESENTATION; FEMALE; MEMORY T LYMPHOCYTE; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; TREATMENT DURATION; TREATMENT OUTCOME; TRYPANOSOMA CRUZI; TRYPANOSOMIASIS;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CHAGAS DISEASE; CROSS-PRIMING; DNA; EPITOPES; FEMALE; MICE; MICE, INBRED C3H; NEURAMINIDASE; PROTOZOAN VACCINES; TIME FACTORS; TOLL-LIKE RECEPTOR 9; TRYPANOSOMA CRUZI;

EID: 34447646950     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2007.05.022     Document Type: Article

References (37)

1. Wong P., and Pamer E.G. CD8 T cell responses to infectious pathogens. Annu Rev Immunol 21 (2003) 29-70
2. Robinson H.L., and Amara R.R. T cell vaccines for microbial infections. Nat Med 11 (2005) S25-S32
3. + cytotoxic T cells after infection with Trypanosoma cruzi in naive or vaccinated mice. Infect Immun 74 (2006) 2477-2482
4. + T-Cell responses to Trypanosoma cruzi are highly focused on strain-variant trans-sialidase epitopes. PLoS Pathog 2 8 (2006) e77
5. Tarleton R.L., Koller B.H., Latour A., and Postan M. Susceptibility of beta 2-microglobulin-deficient mice to Trypanosoma cruzi infection. Nature 356 (1992) 338-340
6. Rottenberg M.E., Bakhiet M., Olsson T., Kristensson K., Mak T., Wigzell H., et al. Differential susceptibilities of mice genomically deleted of CD4 and CD8 to infections with Trypanosoma cruzi or Trypanosoma brucei. Infect Immun 61 (1993) 5129-5133
7. Tarleton R.L., Sun J., Zhang L., Postan M., and Glimcher L. Trypanosoma cruzi infection in MHC-deficient mice: further evidence for the role of both class I- and class II-restricted T cells in immune resistance and disease. Int Immunol 8 (1996) 13-22
8. Rodrigues M.M., Boscardin S.B., Vasconcelos J.R., Hiyane M.I., Salay G., and Soares I.S. Importance of CD8 T cell-mediated immune response during intracellular parasitic infections and its implications for the development of effective vaccines. Ann Acad Bras Cienc 75 (2003) 443-468
9. + T cells in Trypanosoma cruzi infection. Immunol Rev 201 (2004) 304-317
10. Henriques-Pons A., Oliveira G.M., Paiva M.M., Correa A.F., Batista M.M., Bisaggio R.C., et al. Evidence for a perforin-mediated mechanism controlling cardiac inflammation in Trypanosoma cruzi infection. Int J Exp Pathol 83 (2002) 67-79
11. Muller U., Sobek V., Balkow S., Holscher C., Mullbacher A., Museteanu C., et al. Concerted action of perforin and granzymes is critical for the elimination of Trypanosoma cruzi from mouse tissues, but prevention of early host death is in addition dependent on the FasL/Fas pathway. Eur J Immunol 33 (2003) 70-78
12. Garg N., and Tarleton R. Genetic immunization elicits antigen-specific protective immune responses and decreases disease severity in Trypanosoma cruzi infection. Infect Immun 70 (2002) 5547-5555
13. Katae M., Miyahira Y., Takeda K., Matsuda H., Yagita H., Okumura K., et al. Coadministration of an interleukin-12 gene and a Trypanosoma cruzi gene improves vaccine efficacy. Infect Immun 70 (2002) 4833-4840
14. Vasconcelos J.R., Hiyane M.I., Marinho C.R.F., Claser C., Vieira-Machado A.M., Gazinelli R.T., et al. Protective immunity against Trypanosoma cruzi infection in a highly susceptible mouse strain following vaccination with genes encoding the Amastigote Surface Protein-2 and trans-sialidase. Hum Gene Ther 15 (2004) 878-886
15. +-T-cell-dependent control of Trypanosoma cruzi infection in a highly susceptible mouse strain after immunization with recombinant proteins based on amastigote surface protein 2. Infect Immun 73 (2005) 6017-6025
16. +-T-Cell epitope induced by virus vector vaccination can successfully control Trypanosoma cruzi infection. Infect Immun 73 (2005) 7356-7365
17. Machado A.V., Cardoso J.E., Claser C., Rodrigues M.M., Gazzinelli R.T., and Bruna-Romero O. Long-term protective immunity induced against Trypanosoma cruzi infection after vaccination with recombinant adenoviruses encoding Amastigote Surface Protein-2 and trans-sialidase. Hum Gene Ther 17 (2006) 898-908
18. Silva L.H.P., and Nussenzweig V. Sobre uma cepa de Trypanosoma cruzi altamente virulenta para o camundongo branco. Folia Clin Biol 20 (1953) 191-203
19. Krettli A.U., and Brener Z. Protective effects of specific antibodies in Trypanosoma cruzi infections. J Immunol 116 (1976) 755-760
20. Boscardin S.B., Kinoshita S.S., Fujimura A.E., and Rodrigues M.M. Immunization with cDNA expressed by amastigotes of Trypanosoma cruzi elicits protective immune response against experimental infection. Infect Immun 71 (2003) 2744-2757
21. Li S., Rodrigues M., Rodriguez D., Rodriguez J.R., Esteban M., Palese P., et al. Priming with recombinant influenza virus followed by administration of recombinant vaccinia virus induces CD8+ T-cell-mediated protective immunity against malaria. Proc Natl Acad Sci USA 90 (1993) 5214-5218
22. Belz G.T., Wodarz D., Diaz G., Nowak M.A., and Doherty P.C. Compromised influenza virus-specific CD8+-T-cell memory in CD4+-T-cell-deficient mice. J Virol 76 (2002) 12388-12393
23. Sun J.C., and Bevan M.J. Defective CD8 T cell memory following acute infection without CD4 T cell help. Science 300 (2003) 339-342
24. Shedlock D.J., and Shen H. Requirement for CD4 T cell help in generating functional CD8 T cell memory. Science 300 (2003) 337-339
25. + T cell immunity. Nat Immunol 5 (2004) 1143-1148
26. + memory CTLs to become efficient effectors in vivo. J Immunol 172 (2004) 3719-3724
27. Heit A., Schmitz F., O'Keeffe M., Staib C., Busch D.H., Wagner H., et al. Protective CD8 T cell immunity triggered by CpG-protein conjugates competes with the efficacy of live vaccines. J Immunol 174 (2005) 4373-4380
28. + T cell responses. J Immunol 174 (2005) 7676-7683
29. + T cell responses in nonhuman primates. Proc Natl Acad Sci USA 102 (2005) 15190-15194
30. + T cell responses induced by protein immunization in the presence of Montanide ISA720 plus synthetic oligodeoxynucleotides containing immunostimulatory cytosine-guanine dinucleotide motifs. J Infect Dis 193 (2006) 563-572
31. Tritel M., Stoddard A.M., Flynn B.J., Darrah P.A., Wu C.Y., Wille U., et al. Prime-boost vaccination with HIV-1 Gag protein and cytosine phosphate guanosine oligodeoxynucleotide, followed by adenovirus, induces sustained and robust humoral and cellular immune responses. J Immunol 171 (2003) 2538-2547
32. Wille-Reece U., Flynn B.J., Lore K., Koup R.A., Miles A.P., Saul A., et al. Toll-like receptor agonists influence the magnitude and quality of memory T cell responses after prime-boost immunization in nonhuman primates. J Exp Med 203 (2006) 1249-1258
33. Hutchings C.L., Gilbert S.C., Hill A.V., and Moore A.C. Novel protein and poxvirus-based vaccine combinations for simultaneous induction of humoral and cell-mediated immunity. J Immunol 175 (2005) 599-606
34. Heit A., Huster K.M., Schmitz F., Schiemann M., Busch D.H., and Wagner H. CpG-DNA aided cross-priming by cross-presenting B cells. J Immunol 172 (2004) 1501-1507
35. + T lymphocytes by immunostimulatory DNA-based vaccines. J Immunol 168 (2002) 4907-4913
36. Kuchtey J., Chefalo P.J., Gray R.C., Ramachandra L., and Harding C.V. Enhancement of dendritic cell antigen cross-presentation by CpG DNA involves type I IFN and stabilization of class I MHC mRNA. J Immunol 175 (2005) 2244-2251
37. + T cells after acute infection. Nat Immunol 5 (2004) 927-933